These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24662035)

  • 41. The impact of network biology in pharmacology and toxicology.
    Panagiotou G; Taboureau O
    SAR QSAR Environ Res; 2012; 23(3-4):221-35. PubMed ID: 22352466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan?
    Vicini P; van der Graaf PH
    Clin Pharmacol Ther; 2013 May; 93(5):379-81. PubMed ID: 23598453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A cross-species analysis method to analyze animal models' similarity to human's disease state.
    Yu S; Zheng L; Li Y; Li C; Ma C; Li Y; Li X; Hao P
    BMC Syst Biol; 2012; 6 Suppl 3(Suppl 3):S18. PubMed ID: 23282076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug discovery, development and delivery in Alzheimer's disease.
    Brambilla D
    Pharm Res; 2017 Dec; 35(1):3. PubMed ID: 29288429
    [No Abstract]   [Full Text] [Related]  

  • 45. Cellular and molecular biology of Alzheimer's disease and animal models.
    Price DL; Sisodia SS
    Annu Rev Med; 1994; 45():435-46. PubMed ID: 8198393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Animal models in the drug discovery pipeline for Alzheimer's disease.
    Van Dam D; De Deyn PP
    Br J Pharmacol; 2011 Oct; 164(4):1285-300. PubMed ID: 21371009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A systems-based model of Alzheimer's disease.
    Tang Y; Lutz MW; Xing Y
    Alzheimers Dement; 2019 Jan; 15(1):168-171. PubMed ID: 30102884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Experimental models for Alzheimer's disease research].
    Sarasa M
    Rev Neurol; 2006 Mar 1-15; 42(5):297-301. PubMed ID: 16538593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development.
    Geerts H; Spiros A; Roberts P; Carr R
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):257-65. PubMed ID: 23338980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transgenic mouse models of Alzheimer's disease: phenotype and application.
    Higgins GA; Jacobsen H
    Behav Pharmacol; 2003 Sep; 14(5-6):419-38. PubMed ID: 14501255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
    Saxena U
    Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. As drug trials fail, Alzheimer's researchers look toward prevention.
    Rice S
    Mod Healthc; 2014 Jan; 44(4):8-9. PubMed ID: 24640402
    [No Abstract]   [Full Text] [Related]  

  • 53. Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.
    Mayer SC; Kreft AF; Harrison B; Abou-Gharbia M; Antane M; Aschmies S; Atchison K; Chlenov M; Cole DC; Comery T; Diamantidis G; Ellingboe J; Fan K; Galante R; Gonzales C; Ho DM; Hoke ME; Hu Y; Huryn D; Jain U; Jin M; Kremer K; Kubrak D; Lin M; Lu P; Magolda R; Martone R; Moore W; Oganesian A; Pangalos MN; Porte A; Reinhart P; Resnick L; Riddell DR; Sonnenberg-Reines J; Stock JR; Sun SC; Wagner E; Wang T; Woller K; Xu Z; Zaleska MM; Zeldis J; Zhang M; Zhou H; Jacobsen JS
    J Med Chem; 2008 Dec; 51(23):7348-51. PubMed ID: 19012391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.
    Wallace TL; Porter RH
    Biochem Pharmacol; 2011 Oct; 82(8):891-903. PubMed ID: 21741954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteomic analysis of serum proteins in triple transgenic Alzheimer's disease mice: implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early Alzheimer's disease.
    Sui X; Ren X; Huang P; Li S; Ma Q; Ying M; Ni J; Liu J; Yang X
    J Alzheimers Dis; 2014; 40(3):575-86. PubMed ID: 24496070
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform.
    Vaudano E; Vannieuwenhuyse B; Van Der Geyten S; van der Lei J; Visser PJ; Streffer J; Ritchie C; McHale D; Lovestone S; Hofmann-Apitius M; Truyen L; Goldman M
    Alzheimers Dement; 2015 Sep; 11(9):1121-2. PubMed ID: 25754460
    [No Abstract]   [Full Text] [Related]  

  • 57. Mutant mice: experimental organisms as materialised models in biomedicine.
    Huber L; Keuck LK
    Stud Hist Philos Biol Biomed Sci; 2013 Sep; 44(3):385-91. PubMed ID: 23545252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alzheimer's disease--from cause to cure?
    Vines G
    Trends Biotechnol; 1993 Feb; 11(2):49-55. PubMed ID: 7763478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge.
    Geerts H; Dacks PA; Devanarayan V; Haas M; Khachaturian ZS; Gordon MF; Maudsley S; Romero K; Stephenson D;
    Alzheimers Dement; 2016 Sep; 12(9):1014-1021. PubMed ID: 27238630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advanced systems biology methods in drug discovery and translational biomedicine.
    Zou J; Zheng MW; Li G; Su ZG
    Biomed Res Int; 2013; 2013():742835. PubMed ID: 24171171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.